Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] NLMUID: 7513617"" wg kryterium: JN


Tytuł :
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Autorzy :
Andreatta K; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
Willkom M; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
Martin R; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
Chang S; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
Wei L; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
Liu H; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
Liu YP; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
Graham H; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
Quirk E; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
Martin H; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
White KL; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Dec 01; Vol. 74 (12), pp. 3555-3564.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Substitution*
Sustained Virologic Response*
Adenine/*analogs & derivatives
Anti-HIV Agents/*therapeutic use
Emtricitabine/*therapeutic use
HIV Infections/*drug therapy
Heterocyclic Compounds, 4 or More Rings/*therapeutic use
Adenine/therapeutic use ; Adult ; Amino Acid Substitution/genetics ; Double-Blind Method ; Drug Resistance, Multiple, Viral/genetics ; Drug Therapy, Combination ; Genotype ; HIV-1/drug effects ; Humans ; RNA, Viral/blood ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.
Autorzy :
Taramasso L; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.; Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Lorenzini P; HIV/AIDS Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy.
Di Biagio A; Infectious Diseases Clinic, Policlinico San Martino Hospital, Genoa, Italy.
Lichtner M; Department of Infectious Diseases, La Sapienza University, Polo Pontino, Latina, Italy.
Marchetti G; Department of Health Sciences, Clinic of Infectious and Tropical Diseases, University of Milan, Milan, Italy.
Rossotti R; Infectious Diseases Department, ASST GOM Niguarda, Milan, Italy.
Lapadula G; Infectious Diseases Unit, Ospedale San Gerardo, Monza, Italy.
Cozzi-Lepri A; University College London, London, UK.
Vichi F; Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy.
Antinori A; HIV/AIDS Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy.
Bonora S; Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy.
d'Arminio Monforte A; Department of Health Sciences, Clinic of Infectious and Tropical Diseases, University of Milan, Milan, Italy.
Pokaż więcej
Corporate Authors :
ICONA Foundation Study Group
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Nov 01; Vol. 74 (11), pp. 3295-3304.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Anti-HIV Agents/*adverse effects
Anti-HIV Agents/*therapeutic use
HIV Infections/*complications
HIV Infections/*drug therapy
Liver Diseases/*enzymology
Liver Diseases/*etiology
Adult ; Coinfection/drug therapy ; Female ; HIV Integrase Inhibitors/adverse effects ; HIV Integrase Inhibitors/therapeutic use ; HIV Protease Inhibitors/adverse effects ; HIV Protease Inhibitors/therapeutic use ; HIV-1/drug effects ; Hepatitis B Surface Antigens/blood ; Hepatitis C/drug therapy ; Humans ; Incidence ; Male ; Middle Aged ; Prospective Studies ; Regression Analysis ; Reverse Transcriptase Inhibitors/adverse effects ; Reverse Transcriptase Inhibitors/therapeutic use ; Risk Factors
Czasopismo naukowe
Tytuł :
Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study-authors' response.
Autorzy :
Chauveau M; Department of Infectious Disease, CHU Hôtel-Dieu, Nantes, France.
Raffi F; Department of Infectious Disease, CHU Hôtel-Dieu, Nantes, France.; CIC UIC 1413 INSERM, CHU Nantes, France.
Allavena C; Department of Infectious Disease, CHU Hôtel-Dieu, Nantes, France.; CIC UIC 1413 INSERM, CHU Nantes, France.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Nov 01; Vol. 74 (11), pp. 3403-3404.
Typ publikacji :
Letter; Comment
MeSH Terms :
Anti-HIV Agents*
HIV Infections*
Emtricitabine ; Humans ; Prospective Studies ; Rilpivirine ; Tenofovir
Opinia redakcyjna
Tytuł :
Comment on: Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study.
Autorzy :
Gatanaga H; AIDS Clinical Centre, National Centre for Global Health and Medicine, Tokyo, Japan.
Oka S; AIDS Clinical Centre, National Centre for Global Health and Medicine, Tokyo, Japan.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Nov 01; Vol. 74 (11), pp. 3402-3403.
Typ publikacji :
Letter; Comment
MeSH Terms :
Anti-HIV Agents*
HIV Infections*
Emtricitabine ; Humans ; Prospective Studies ; Rilpivirine ; Tenofovir
Opinia redakcyjna
Tytuł :
Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France.
Autorzy :
Potard V; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.; INSERM-TRANSFERT, Paris, France.
Canestri A; AP-HP, Hôpital de Tenon, Service des Maladies Infectieuses et Tropicales, Paris, France.
Gallien S; AP-HP, Hôpital Henri Mondor, Service d'Immunologie et Maladies Infectieuses, Université Paris Est Créteil, Inserm U955, Créteil, France.
Costagliola D; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Pokaż więcej
Corporate Authors :
French Hospital Database on HIV
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Nov 01; Vol. 74 (11), pp. 3305-3314.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Darunavir/*therapeutic use
HIV Infections/*drug therapy
HIV Protease Inhibitors/*therapeutic use
Practice Patterns, Physicians'/*statistics & numerical data
Adult ; CD4 Lymphocyte Count ; Female ; France ; HIV-1 ; Humans ; Male ; Middle Aged ; Treatment Failure ; Viral Load/drug effects
Czasopismo naukowe
Tytuł :
Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda.
Autorzy :
Omooja J; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.; Department of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda.
Nannyonjo M; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
Sanyu G; Uganda Virus Research Institute, Entebbe, Uganda.
Nabirye SE; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
Nassolo F; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
Lunkuse S; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
Kapaata A; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
Segujja F; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.; Department of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda.
Kateete DP; Department of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda.; Department of Immunology and Molecular Biology, College of Health Sciences, Makerere University, Kampala, Uganda.
Ssebaggala E; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
Bbosa N; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
Aling E; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
Nsubuga RN; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
Kaleebu P; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.; Uganda Virus Research Institute, Entebbe, Uganda.
Ssemwanga D; Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) and London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.; Uganda Virus Research Institute, Entebbe, Uganda.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Oct 01; Vol. 74 (10), pp. 3021-3029.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-HIV Agents/*therapeutic use
Drug Resistance, Viral/*drug effects
HIV Infections/*drug therapy
HIV-1/*drug effects
Adult ; Female ; HIV Seropositivity/drug therapy ; Humans ; Male ; Mutation/drug effects ; Nevirapine/therapeutic use ; Reverse Transcriptase Inhibitors/therapeutic use ; Treatment Failure ; Treatment Outcome ; Uganda ; Viral Load/drug effects ; Zidovudine/therapeutic use
Czasopismo naukowe
Tytuł :
Pre-treatment and acquired HIV drug resistance in Dar es Salaam, Tanzania in the era of tenofovir and routine viral load monitoring.
Autorzy :
Barabona G; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Mahiti M; International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan.; St Francis University College of Health and Allied Sciences, Ifakara, Tanzania.; Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Masoud S; Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Mbelele P; Kibong'oto Infectious Diseases Hospital, Moshi, Tanzania.
Mgunya AS; Muhimbili National Hospital, Dar es Salaam, Tanzania.
Minja L; Muhimbili National Hospital, Dar es Salaam, Tanzania.
Sunguya B; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.; Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Shigemi U; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Matsuda M; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Hachiya A; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Iwatani Y; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.; Nagoya University Graduate School of Medicine, Nagoya, Japan.
Lyamuya E; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.; Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Ueno T; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.; International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Oct 01; Vol. 74 (10), pp. 3016-3020.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-HIV Agents/*therapeutic use
Drug Resistance, Viral/*drug effects
HIV Infections/*drug therapy
HIV-1/*drug effects
Reverse Transcriptase Inhibitors/*therapeutic use
Tenofovir/*therapeutic use
Viral Load/*drug effects
Adult ; Antiretroviral Therapy, Highly Active/methods ; Cross-Sectional Studies ; Female ; Humans ; Male ; Middle Aged ; Tanzania ; Treatment Failure
Czasopismo naukowe
Tytuł :
Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study.
Autorzy :
Mehta K; Center for Translational Medicine, University of Maryland, Baltimore, MD, USA.
Ravimohan S; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Pasipanodya JG; Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA.
Srivastava S; Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA.
Modongo C; Pennsylvania Botswana-UPenn Partnership, Gaborone, Botswana.
Zetola NM; Pennsylvania Botswana-UPenn Partnership, Gaborone, Botswana.
Weissman D; University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
Ivaturi V; Center for Translational Medicine, University of Maryland, Baltimore, MD, USA.
Gumbo T; Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA.
Bisson GP; University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
Vinnard C; Public Health Research Institute, New Jersey Medical School, Newark, NJ, USA.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Oct 01; Vol. 74 (10), pp. 2994-3002.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antitubercular Agents/*administration & dosage
Antitubercular Agents/*pharmacokinetics
Coinfection/*drug therapy
Ethambutol/*administration & dosage
Ethambutol/*pharmacokinetics
HIV Infections/*drug therapy
Tuberculosis, Pulmonary/*drug therapy
Adult ; Biological Availability ; Botswana ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies
Czasopismo naukowe
Tytuł :
Evaluation of HIV-1 reservoir levels as possible markers for virological failure during boosted darunavir monotherapy.
Autorzy :
Rutsaert S; HIV Cure Research Center, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
De Spiegelaere W; Department of Morphology, Faculty of Veterinary Medicine, Ghent University, Ghent, Belgium.
De Clercq L; HIV Cure Research Center, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Vandekerckhove L; HIV Cure Research Center, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Oct 01; Vol. 74 (10), pp. 3030-3034.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-HIV Agents/*therapeutic use
Darunavir/*therapeutic use
HIV Infections/*drug therapy
HIV Infections/*virology
HIV-1/*drug effects
Adult ; Female ; Humans ; Male ; Middle Aged ; RNA, Viral/genetics ; Retrospective Studies ; Ritonavir/therapeutic use ; Treatment Failure ; Viral Load/drug effects
Czasopismo naukowe
Tytuł :
An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy.
Autorzy :
Geretti AM; Institute of Infection & Global Health, University of Liverpool, Liverpool, UK.
Abdullahi A; Institute of Infection & Global Health, University of Liverpool, Liverpool, UK.
Mafotsing Fopoussi O; Institute of Infection & Global Health, University of Liverpool, Liverpool, UK.; Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention & Management (CIRCB), Yaoundé, Cameroon.
Bonnett L; Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Defo VF; Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention & Management (CIRCB), Yaoundé, Cameroon.; Hôpital Central Yaoundé, Ministry of Public Health, Yaoundé, Cameroon.
Moudourou S; Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention & Management (CIRCB), Yaoundé, Cameroon.
Fokam J; Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention & Management (CIRCB), Yaoundé, Cameroon.
Kouanfack C; Hôpital Central Yaoundé, Ministry of Public Health, Yaoundé, Cameroon.
Torimiro J; Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention & Management (CIRCB), Yaoundé, Cameroon.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Oct 01; Vol. 74 (10), pp. 3011-3015.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-HIV Agents/*therapeutic use
DNA, Viral/*genetics
Drug Resistance, Viral/*genetics
HIV Infections/*drug therapy
HIV-1/*drug effects
HIV-1/*genetics
Mutation/*genetics
Adult ; Antiretroviral Therapy, Highly Active/methods ; Cameroon ; Darunavir/therapeutic use ; Drug Resistance, Viral/drug effects ; Drug Therapy, Combination/methods ; Female ; HIV Infections/virology ; Humans ; Male ; Middle Aged ; Reverse Transcriptase Inhibitors/pharmacology ; Ritonavir/therapeutic use ; Viral Load/drug effects ; Viral Load/genetics
Czasopismo naukowe
Tytuł :
Long-term virological outcomes, failure and acquired resistance in a large cohort of Ugandan children.
Autorzy :
Huibers MHW; Global Child Health Group, Emma Children's Hospital, Amsterdam UMC, The Netherlands.; Amsterdam Institute of Global Health Development (AIGHD), Amsterdam, The Netherlands.
Kityo C; Joint Clinical Research Centre (JCRC), Kampala, Uganda.
Boerma RS; Amsterdam Institute of Global Health Development (AIGHD), Amsterdam, The Netherlands.
Kaudha E; Joint Clinical Research Centre (JCRC), Kampala, Uganda.
Sigaloff KCE; Amsterdam Institute of Global Health Development (AIGHD), Amsterdam, The Netherlands.; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.
Balinda SN; Joint Clinical Research Centre (JCRC), Kampala, Uganda.
Bertagnolio S; World Health Organization, HIV/AIDS Department, Geneva, Switzerland.
Nakanjako R; Joint Clinical Research Centre (JCRC), Kampala, Uganda.
Mugyenyi P; Joint Clinical Research Centre (JCRC), Kampala, Uganda.
Calis JCJ; Global Child Health Group, Emma Children's Hospital, Amsterdam UMC, The Netherlands.; Department of Pediatric Intensive Care, Emma Children's Hospital, Amsterdam UMC location AMC, The Netherlands.; Department of Paediatrics and Child Health, College of Medicine, Blantyre, Malawi.
Boele van Hensbroek M; Global Child Health Group, Emma Children's Hospital, Amsterdam UMC, The Netherlands.
Rinke de Wit TF; Amsterdam Institute of Global Health Development (AIGHD), Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Oct 01; Vol. 74 (10), pp. 3035-3043.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-HIV Agents/*therapeutic use
Drug Resistance, Viral/*drug effects
HIV Infections/*drug therapy
African Continental Ancestry Group ; Child, Preschool ; Female ; HIV-1/drug effects ; Humans ; Male ; Treatment Failure ; Uganda ; Viral Load
Czasopismo naukowe
Tytuł :
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
Autorzy :
Katlama C; Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Pitié-Salpêtrière, Service des Maladies Infectieuses et Tropicales, Paris, France.; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Assoumou L; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Valantin MA; Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Pitié-Salpêtrière, Service des Maladies Infectieuses et Tropicales, Paris, France.; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Soulié C; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.; APHP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Paris, France.
Martinez E; Infectious Diseases Unit, Hospital Clinic and University of Barcelona, Spain.
Béniguel L; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Bouchaud O; Assistance Publique-Hôpitaux de Paris (APHP), Centre Hospitalier Universitaire Avicenne, Service des Maladies Infectieuses et Tropicales, Bobigny, France.; Université Paris 13, IMEA-Fondation Internationale Léon Mba, Paris, France.
Raffi F; INSERM CIC 1413, Université de Nantes, Département des Maladies Infectieuses, Hôpital Hôtel-Dieu, Nantes, France.
Molina JM; Université Paris Diderot, Paris, France, Sorbonne Paris Cité, APHP, Hôpital Saint-Louis, Paris, France.
Fellahi S; Sorbonne Université, INSERM UMRS_938, Institut Hospitalo-Universitaire de Cardio-métabolisme et Nutrition (ICAN), Paris, France.
Peytavin G; INSERM UMR 1137, Université Paris 7, Laboratoire de Pharmacologie-Toxicologie, Hôpital Bichat-Claude Bernard, APHP, Paris, France.
Marcelin AG; APHP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Paris, France.
Kolta S; Département de rhumatologie, Hôpital Cochin, Paris, France - INSERM UMR-1153, Paris, France.
Capeau J; Sorbonne Université, INSERM UMRS_938, Institut Hospitalo-Universitaire de Cardio-métabolisme et Nutrition (ICAN), Paris, France.
Gibowski S; ANRS, France Recherche Nord & Sud Sida-HIV Hépatites, Agence autonome de l'INSERM, Paris, France.
Cardon F; ANRS, France Recherche Nord & Sud Sida-HIV Hépatites, Agence autonome de l'INSERM, Paris, France.
Reynes J; Département de maladies infectieuses, UMI 233 INSERM U1175, CHU de Montpellier, Montpellier, France.
Costagliola D; Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Pokaż więcej
Corporate Authors :
members of the ANRS 163 ETRAL study
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Sep 01; Vol. 74 (9), pp. 2742-2751.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
HIV Infections/*drug therapy
HIV Infections/*virology
Pyridazines/*therapeutic use
Raltegravir Potassium/*therapeutic use
Antiretroviral Therapy, Highly Active ; Biomarkers ; CD4 Lymphocyte Count ; Female ; HIV Infections/transmission ; HIV Integrase Inhibitors/administration & dosage ; HIV Integrase Inhibitors/adverse effects ; HIV Integrase Inhibitors/therapeutic use ; HIV Protease Inhibitors/administration & dosage ; HIV Protease Inhibitors/adverse effects ; HIV Protease Inhibitors/therapeutic use ; Humans ; Male ; Medication Adherence ; Middle Aged ; Nitriles ; Pyridazines/administration & dosage ; Pyridazines/adverse effects ; Pyrimidines ; Quality of Life ; Raltegravir Potassium/administration & dosage ; Raltegravir Potassium/adverse effects ; Reverse Transcriptase Inhibitors/administration & dosage ; Reverse Transcriptase Inhibitors/adverse effects ; Reverse Transcriptase Inhibitors/therapeutic use ; Time Factors ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Tytuł :
Impact of prolonged maraviroc treatment on non-AIDS-related comorbidities in HIV-positive patients: a retrospective cohort study.
Autorzy :
Piconi S; First Infectious Diseases Department, Ospedale Luigi Sacco, Milano, Italy.
Foschi A; First Infectious Diseases Department, Ospedale Luigi Sacco, Milano, Italy.
Malagoli A; Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Modena, Italy.
Carli F; HIV Metabolic Clinic, Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Zona S; HIV Metabolic Clinic, Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Milic J; HIV Metabolic Clinic, Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Ricci ED; First Infectious Diseases Department, Ospedale Luigi Sacco, Milano, Italy.
Rizzardini G; First Infectious Diseases Department, Ospedale Luigi Sacco, Milano, Italy.
Guaraldi G; HIV Metabolic Clinic, Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Sep 01; Vol. 74 (9), pp. 2723-2731.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-HIV Agents/*therapeutic use
HIV Infections/*drug therapy
HIV Infections/*epidemiology
Maraviroc/*therapeutic use
Adult ; Anti-HIV Agents/adverse effects ; Antiretroviral Therapy, Highly Active/adverse effects ; CCR5 Receptor Antagonists/adverse effects ; CCR5 Receptor Antagonists/therapeutic use ; CD4 Lymphocyte Count ; Comorbidity ; Female ; HIV Infections/complications ; HIV Infections/virology ; Humans ; Incidence ; Male ; Maraviroc/adverse effects ; Middle Aged ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Tytuł :
Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART.
Autorzy :
Rawizza HE; Brigham and Women's Hospital, Boston, MA, USA.; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Darin KM; Northwestern University School of Professional Studies, Chicago, IL, USA.
Oladokun R; College of Medicine, University of Ibadan, University College Hospital, Ibadan, Nigeria.
Brown B; College of Medicine, University of Ibadan, University College Hospital, Ibadan, Nigeria.
Ogunbosi B; College of Medicine, University of Ibadan, University College Hospital, Ibadan, Nigeria.
David N; Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Akanmu S; University of Lagos, Lagos State, Nigeria.
Olaitan O; APIN Public Health Initiatives, Abuja, Nigeria.
Chang C; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Scarsi KK; University of Nebraska Medical Center, Omaha, NE, USA.
Okonkwo P; APIN Public Health Initiatives, Abuja, Nigeria.
Kanki PJ; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Sep 01; Vol. 74 (9), pp. 2707-2715.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :
Antibiotics, Antitubercular/*therapeutic use
Coinfection/*drug therapy
HIV Infections/*drug therapy
Lopinavir/*therapeutic use
Rifabutin/*therapeutic use
Ritonavir/*therapeutic use
Tuberculosis/*drug therapy
Antibiotics, Antitubercular/administration & dosage ; Antibiotics, Antitubercular/adverse effects ; Antiretroviral Therapy, Highly Active ; Biomarkers ; Drug Interactions ; Drug-Related Side Effects and Adverse Reactions/diagnosis ; Drug-Related Side Effects and Adverse Reactions/etiology ; Female ; HIV Infections/virology ; Humans ; Male ; Retrospective Studies ; Rifabutin/administration & dosage ; Rifabutin/adverse effects ; Treatment Outcome ; Tuberculosis/microbiology
Czasopismo naukowe
Tytuł :
First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine.
Autorzy :
Siguier M; Hôpital Saint-Louis, Department of Infectious Diseases and University Paris Diderot, Paris, France.
Mera R; Gilead Sciences, Epidemiology, Foster City, CA, USA.
Pialoux G; Hôpital Tenon, Department of Infectious Diseases, Paris, France.
Ohayon M; Le 190, Paris, France.
Cotte L; Hôpital Croix Rousse, Department of Infectious Diseases, Lyon, France.
Valin N; Hôpital Saint-Antoine, Department of Infectious Diseases, Paris, France.
Ghosn J; Hôtel Dieu, Department of Infectious Diseases, Paris, France.
Cua E; Hôpital L'Archet, Department of Infectious Diseases, Nice, France.
Pintado C; Hôpital Saint-Louis, Department of Infectious Diseases and University Paris Diderot, Paris, France.
Chas J; Hôpital Tenon, Department of Infectious Diseases, Paris, France.
Barriere G; Gilead Sciences S.A.S., Boulogne-Billancourt, France.
Durand F; Gilead Sciences S.A.S., Boulogne-Billancourt, France.
Molina JM; Hôpital Saint-Louis, Department of Infectious Diseases and University Paris Diderot, Paris, France.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Sep 01; Vol. 74 (9), pp. 2752-2758.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Health Plan Implementation*
Pre-Exposure Prophylaxis*/methods
Anti-HIV Agents/*administration & dosage
Emtricitabine/*administration & dosage
HIV Infections/*prevention & control
Tenofovir/*administration & dosage
Adult ; Comorbidity ; Female ; France/epidemiology ; HIV Infections/epidemiology ; Homosexuality, Male ; Humans ; Male ; Middle Aged ; Odds Ratio ; Outcome Assessment, Health Care ; Unsafe Sex
Czasopismo naukowe
Tytuł :
Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study.
Autorzy :
Valantin MA; AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Service des Maladies Infectieuses, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP UMRS 1136), F-75013, Paris, France.
Durand L; GH Pitié-Salpêtrière APHP, Pharmacy, Paris, France.
Wirden M; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, F-75013, Paris, France.
Assoumou L; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
Caby F; AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Service des Maladies Infectieuses, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP UMRS 1136), F-75013, Paris, France.
Soulié C; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, F-75013, Paris, France.
Nguyen TT; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, F-75013, Paris, France.
Tubiana R; AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Service des Maladies Infectieuses, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP UMRS 1136), F-75013, Paris, France.
Kirstetter M; AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Service des Maladies Infectieuses, Paris, France.
Junot H; GH Pitié-Salpêtrière APHP, Pharmacy, Paris, France.
Marcelin AG; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, F-75013, Paris, France.
Peytavin G; IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Pharmacologie-Toxicologie, Hôpital Bichat Claude-Bernard, Paris, France.
Tilleul P; GH Pitié-Salpêtrière APHP, Pharmacy, Paris, France.; Paris Descartes Université, Pharmacie Clinique, Faculté de Pharmacie, Paris, France.
Katlama C; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP UMRS 1136), AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Service des Maladies Infectieuses, F-75013, Paris, France.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Sep 01; Vol. 74 (9), pp. 2716-2722.
Typ publikacji :
Journal Article
MeSH Terms :
Anti-HIV Agents/*therapeutic use
HIV Infections/*drug therapy
Adult ; Aged ; Anti-HIV Agents/pharmacology ; Antiretroviral Therapy, Highly Active ; CD4 Lymphocyte Count ; Drug Resistance, Viral ; Female ; HIV Infections/immunology ; HIV Infections/virology ; HIV-1/drug effects ; Humans ; Male ; Middle Aged ; Prospective Studies ; Treatment Outcome ; Viral Load ; Young Adult
Czasopismo naukowe
Tytuł :
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
Autorzy :
Gianotti N; Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy.
Lorenzini P; Clinical Division, National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS, Rome, Italy.
Cozzi-Lepri A; Institute for Global Health, University College London, London, UK.
De Luca A; Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Madeddu G; Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.
Sighinolfi L; Department of Infectious Diseases, S. Anna Hospital, Ferrara, Italy.
Pinnetti C; Clinical Division, National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS, Rome, Italy.
Santoro C; Clinic of Infectious Diseases, University of Bari, University Hospital Policlinico, Bari, Italy.
Meraviglia P; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy.
Mussini C; Infectious Disease Clinic, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Modena, Italy.
Antinori A; Clinical Division, National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS, Rome, Italy.
d'Arminio Monforte A; Clinic of Infectious and Tropical Diseases, ASST Santi Paolo and Carlo, Department of Health Sciences, University of Milan, Milan, Italy.
Pokaż więcej
Corporate Authors :
ICONA Foundation Study Group
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Sep 01; Vol. 74 (9), pp. 2732-2741.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CD4 Lymphocyte Count*
Viral Load*
Anti-HIV Agents/*therapeutic use
HIV Infections/*drug therapy
HIV Infections/*virology
AIDS-Related Opportunistic Infections ; Adult ; Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/adverse effects ; Antiretroviral Therapy, Highly Active ; Coinfection ; Female ; HIV Infections/immunology ; HIV Infections/transmission ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Treatment Failure ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
Autorzy :
Alghamdi WA; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.; Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Antwi S; Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.; Department of Child Health, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Enimil A; Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.; Department of Child Health, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Yang H; Department of Biostatistics and Computational Biology, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA.
Dompreh A; Directorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Wiesner L; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Langaee T; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Peloquin CA; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Kwara A; College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Sep 01; Vol. 74 (9), pp. 2698-2706.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Coinfection*
Pharmacogenomic Testing*
Anti-HIV Agents/*pharmacokinetics
Benzoxazines/*pharmacokinetics
HIV Infections/*drug therapy
Reverse Transcriptase Inhibitors/*pharmacokinetics
Adolescent ; Alkynes ; Anti-HIV Agents/administration & dosage ; Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; Benzoxazines/administration & dosage ; Biological Variation, Individual ; Child ; Child, Preschool ; Cyclopropanes ; Drug Interactions ; Drug Monitoring ; Female ; Genotype ; HIV Infections/genetics ; HIV Infections/virology ; Humans ; Male ; Models, Theoretical ; Pharmacogenomic Variants ; Reverse Transcriptase Inhibitors/administration & dosage ; Tuberculosis/drug therapy ; Tuberculosis/microbiology
Czasopismo naukowe
Tytuł :
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence.
Autorzy :
Courlet P; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Decosterd LA; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Brown JA; Molecular Virology, Department Biomedicine Haus Petersplatz, University of Basel, Basel, Switzerland.
Alves Saldanha S; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Marzolini C; Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel and University of Basel, Basel, Switzerland.
Cavassini M; Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Stoeckle M; Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel and University of Basel, Basel, Switzerland.
Csajka C; Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.; School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland.
Labhardt ND; Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital of Basel and University of Basel, Basel, Switzerland.; Clinical Research Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Calmy A; Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland.
Pokaż więcej
Corporate Authors :
Swiss HIV Cohort Study
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Aug 01; Vol. 74 (8), pp. 2468-2470.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Treatment Adherence and Compliance*
Anti-HIV Agents/*analysis
Emtricitabine/*analysis
HIV Infections/*drug therapy
Lamivudine/*analysis
Saliva/*chemistry
Anti-HIV Agents/therapeutic use ; Chemistry Techniques, Analytical ; Cohort Studies ; Emtricitabine/therapeutic use ; Humans ; Lamivudine/therapeutic use ; Plasma/chemistry ; Specimen Handling
Raport
Tytuł :
Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.
Autorzy :
Rabie H; Department of Paediatrics and Child Health and Children's Infectious Diseases Clinical Research Unit, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
Rawizza H; Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
Zuidewind P; Department of Paediatrics and Child Health and Children's Infectious Diseases Clinical Research Unit, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
Winckler J; Department of Paediatrics and Child Health, and Medical Research Council Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.
Zar H; Department of Paediatrics and Child Health, and Medical Research Council Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.
Van Rie A; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; International Health Unit, Epidemiology and Social Medicine, Faculty of Medicine, University of Antwerp, Antwerp, Belgium.
Wiesner L; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
McIlleron H; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Aug 01; Vol. 74 (8), pp. 2347-2351.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-HIV Agents/*pharmacokinetics
Antibiotics, Antitubercular/*administration & dosage
HIV Infections/*drug therapy
Lopinavir/*pharmacokinetics
Rifampin/*administration & dosage
Ritonavir/*pharmacokinetics
Tuberculosis/*drug therapy
Alanine Transaminase/blood ; Anti-HIV Agents/administration & dosage ; Anti-HIV Agents/adverse effects ; Antibiotics, Antitubercular/adverse effects ; Child ; Child, Preschool ; Drug Combinations ; Female ; HIV Infections/complications ; Humans ; Infant ; Infant, Newborn ; Lopinavir/administration & dosage ; Lopinavir/adverse effects ; Male ; Plasma/chemistry ; Prospective Studies ; Rifampin/adverse effects ; Ritonavir/administration & dosage ; Ritonavir/adverse effects ; Treatment Outcome ; Tuberculosis/complications
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies